Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Tibotec Pharmaceuticals, Ireland
ClinicalTrials.gov Identifier:
NCT00543725
First received: October 11, 2007
Last updated: March 3, 2016
Last verified: March 2016
Results First Received: June 14, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: HIV Infections
HIV-1
Interventions: Drug: TMC278
Drug: efavirenz

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
A phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600mg q.d. in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors in antiretroviral-naïve HIV-1 infected subjects

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
680 participants were randomized (340 in TMC 278 and 340 in efavirenz) but only 338 participants were treated with efavirenz (2 were randomized but not treated).

Reporting Groups
  Description
TMC278 25 mg tablet once daily
Efavirenz 600 mg once daily

Participant Flow:   Overall Study
    TMC278   Efavirenz
STARTED   340   338 
COMPLETED   272   264 
NOT COMPLETED   68   74 
Adverse Event                18                27 
Sponsor's Decision                0                1 
Subject Non-Compliant                4                4 
Subject Ineligible To Continue The Trial                2                0 
Subject Reached A Virologic Endpoint                22                14 
Protocol Violation                0                1 
Withdrawal by Subject                4                13 
Lost to Follow-up                15                11 
Not specified                3                3 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
TMC278 25 mg tablet once daily
Efavirenz 600 mg once daily
Total Total of all reporting groups

Baseline Measures
   TMC278   Efavirenz   Total 
Overall Participants Analyzed 
[Units: Participants]
 340   338   678 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   339   337   676 
>=65 years   1   1   2 
Age 
[Units: Years]
Mean (Standard Deviation)
 36.7  (9.39)   36.4  (8.92)   36.5  (9.15) 
Gender 
[Units: Participants]
     
Female   90   94   184 
Male   250   244   494 
Region Enroll 
[Units: Participants]
     
Africa   19   38   57 
Asia   59   61   120 
Latin America   90   85   175 
USA, Canada, Europe, Australia   172   154   326 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 48   [ Time Frame: Week 48 ]

2.  Secondary:   Number of Participants With Virological Response (Intent-to-Treat - Snapshot, <50 Copies Per mL) at Week 48   [ Time Frame: Week 48 ]

3.  Secondary:   Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 96   [ Time Frame: Week 96 ]

4.  Secondary:   Number of Participants With Virological Response (Intent-to-Treat - Snapshot, <50 Copies Per mL) at Week 96   [ Time Frame: Week 96 ]

5.  Secondary:   Number of Participants With Virological Response (Observed, <50 Copies/mL) at Last On-Treatment Visit (Post-Week 96).   [ Time Frame: Variable, ranging from 3 months up to maximum 18 months for TMC278 and 12 months for Efavirenz ]

6.  Secondary:   Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <400 Copies Per mL) at Week 48   [ Time Frame: Week 48 ]

7.  Secondary:   Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <400 Copies Per mL) at Week 96   [ Time Frame: Week 96 ]

8.  Secondary:   Mean Change From Baseline to Week 48 and Week 96 in Absolute and Relative CD4+ Cell Counts (Using Imputed Data)   [ Time Frame: Baseline, Week 48, and Week 96 ]

9.  Secondary:   Number of Participants With Virologic Failure for the Resistance Determinations by Developing Mutations: First Available On-Treatment Genotypic Data After Failure   [ Time Frame: Week 96 ]


  Serious Adverse Events


  Other Adverse Events
  Hide Other Adverse Events

Time Frame Up to 164 weeks for participants in the TMC278 treatment group and up to 144 weeks for participants in the efavirenz treatment group.
Additional Description Only participants who had at least one of the treatment-emergent adverse events (TEAEs) listed in the Other (non Serious) adverse event (AE) table are included in the total number of participants with Non-Serious AEs.

Frequency Threshold
Threshold above which other adverse events are reported   5  

Reporting Groups
  Description
TMC278 25 mg tablet once daily
Efavirenz 600 mg once daily

Other Adverse Events
    TMC278   Efavirenz
Total, other (not including serious) adverse events     
# participants affected / at risk   253/340 (74.41%)   259/338 (76.63%) 
Gastrointestinal disorders     
Nausea * 1     
# participants affected / at risk   57/340 (16.76%)   67/338 (19.82%) 
Diarrhoea * 1     
# participants affected / at risk   49/340 (14.41%)   53/338 (15.68%) 
Vomiting * 1     
# participants affected / at risk   22/340 (6.47%)   26/338 (7.69%) 
General disorders     
Fatigue * 1     
# participants affected / at risk   20/340 (5.88%)   29/338 (8.58%) 
Pyrexia * 1     
# participants affected / at risk   15/340 (4.41%)   17/338 (5.03%) 
Infections and infestations     
Nasopharyngitis * 1     
# participants affected / at risk   50/340 (14.71%)   47/338 (13.91%) 
Upper respiratory tract infection * 1     
# participants affected / at risk   43/340 (12.65%)   37/338 (10.95%) 
Bronchitis * 1     
# participants affected / at risk   31/340 (9.12%)   6/338 (1.78%) 
Influenza * 1     
# participants affected / at risk   32/340 (9.41%)   30/338 (8.88%) 
Pharyngitis * 1     
# participants affected / at risk   20/340 (5.88%)   14/338 (4.14%) 
Anogenital warts * 1     
# participants affected / at risk   17/340 (5.00%)   14/338 (4.14%) 
Sinusitis * 1     
# participants affected / at risk   17/340 (5.00%)   19/338 (5.62%) 
Musculoskeletal and connective tissue disorders     
Back pain * 1     
# participants affected / at risk   16/340 (4.71%)   30/338 (8.88%) 
Arthralgia * 1     
# participants affected / at risk   10/340 (2.94%)   17/338 (5.03%) 
Nervous system disorders     
Headache * 1     
# participants affected / at risk   61/340 (17.94%)   53/338 (15.68%) 
Dizziness * 1     
# participants affected / at risk   42/340 (12.35%)   111/338 (32.84%) 
Somnolence * 1     
# participants affected / at risk   17/340 (5.00%)   28/338 (8.28%) 
Psychiatric disorders     
Insomnia * 1     
# participants affected / at risk   38/340 (11.18%)   21/338 (6.21%) 
Abnormal dreams * 1     
# participants affected / at risk   19/340 (5.59%)   26/338 (7.69%) 
Depression * 1     
# participants affected / at risk   24/340 (7.06%)   19/338 (5.62%) 
Respiratory, thoracic and mediastinal disorders     
Cough * 1     
# participants affected / at risk   33/340 (9.71%)   15/338 (4.44%) 
Pharyngolaryngeal pain * 1     
# participants affected / at risk   19/340 (5.59%)   6/338 (1.78%) 
Skin and subcutaneous tissue disorders     
Rash * 1     
# participants affected / at risk   15/340 (4.41%)   49/338 (14.50%) 
Pruritus * 1     
# participants affected / at risk   15/340 (4.41%)   17/338 (5.03%) 
Vascular disorders     
Hypertension * 1     
# participants affected / at risk   23/340 (6.76%)   12/338 (3.55%) 
* Events were collected by non-systematic assessment
1 Term from vocabulary, MedDRA 11.0



  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Medical Leader
Organization: Janssen Infectious Diseases BVBA
phone: 32 14 641418


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Tibotec Pharmaceuticals, Ireland
ClinicalTrials.gov Identifier: NCT00543725     History of Changes
Obsolete Identifiers: NCT00614692
Other Study ID Numbers: CR002704
TMC278-TIDP6-C215 ( Other Identifier: Tibotec Pharmaceuticals, Ireland )
Study First Received: October 11, 2007
Results First Received: June 14, 2011
Last Updated: March 3, 2016
Health Authority: United States: Food and Drug Administration
Ireland: Irish Agriculture and Food Development Authority
Canada: Health Canada
China: Food and Drug Administration
Great Britain: Medicines and Healthcare Products Regulatory Agency
United States: Federal Government
Great Britain: Research Ethics Committee